Cipla slashes prices of anticancers in India
This article was originally published in Scrip
Executive Summary
Cipla has announced price cuts of about 60% or more across a clutch of oncology products, including its generic version of AstraZeneca's lung cancer therapy, Iressa (gefitinib), in India.